Prof Evangelos Terpos discusses EAE115 - a phase 2 investigator-initiated study of isatuximab in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients who had received one prior line of therapy.

The study investigated the effectiveness and safety of this triple combination as a second-line treatment for patients who had previously been treated with lenalidomide.

The results showed that isatuximab, pomalidomide, and dexamethasone could be a beneficial treatment option for these patients.

Prof Terpos notes that a longer follow-up is needed to better understand the full extent of the combination's effectiveness in this patient population.